ADC Therapeutics (ADCT) Interest Expenses (2020 - 2026)
ADC Therapeutics (ADCT) posted Interest Expenses of $12.3 million for Q1 2026, up 151.13% sequentially from -$24.2 million in Q4 2025, and up 0.97% YoY from $12.2 million in Q1 2025.
ADC Therapeutics (ADCT) Interest Expenses (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Interest Expenses for 7 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Interest Expenses rose 0.97% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (down 65.09% YoY) and the FY2025 annual result came in at $251.0 million, up 14.16% from the prior year.
- Interest Expenses rose to $12.3 million in Q1 2026 per ADCT's latest filing, from -$24.2 million in the prior quarter.
- Over five years, Interest Expenses peaked at $34.9 million in Q4 2023 and troughed at -$24.2 million in Q4 2025.
- A 5-year average of $10.0 million and a median of $12.2 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 972.31% in 2023, then slumped 742.34% in 2025.
- Over 5 years, Interest Expenses stood at $3.3 million in 2022, then jumped by 972.31% to $34.9 million in 2023, then plunged by 89.22% to $3.8 million in 2024, then plunged by 742.34% to -$24.2 million in 2025, then jumped by 151.13% to $12.3 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $12.3 million, -$24.2 million, and $13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | 13.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.51 Mn |
| Jun 30, 2026 | 13.51 Mn |
| Mar 31, 2026 | 12.35 Mn |
| Mar 31, 2026 | 12.35 Mn |
| Dec 31, 2025 | -24.15 Mn |
| Dec 31, 2025 | -24.15 Mn |
| Sep 30, 2025 | 13.39 Mn |
| Sep 30, 2025 | 13.39 Mn |
| Jun 30, 2025 | 13.00 Mn |
| Jun 30, 2025 | 13.00 Mn |
| Mar 31, 2025 | 12.23 Mn |
| Mar 31, 2025 | 12.23 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Dec 31, 2024 | 3.76 Mn |
| Sep 30, 2024 | 13.12 Mn |
| Sep 30, 2024 | 13.12 Mn |
| Jun 30, 2024 | 12.68 Mn |
| Jun 30, 2024 | 12.68 Mn |
| Mar 31, 2024 | 12.50 Mn |
| Mar 31, 2024 | 12.50 Mn |